Advertisement

Cancer and Metastasis Reviews

, Volume 37, Issue 2–3, pp 237–243 | Cite as

Eicosanoids in prostate cancer

  • Athanassios A. Panagiotopoulos
  • Konstantina Kalyvianaki
  • Elias Castanas
  • Marilena KampaEmail author
Article

Abstract

Many epidemiological studies revealed an association of dietary consumption of fatty acids and prostate cancer. Linoleic acid and alpha-linolenic acid and their derivatives such as arachidonic acid and eicosapentanoic acid are important polyunsaturated fatty acids in animal fats and in many vegetable oils. Their metabolism at the cellular level by enzymes such as lipoxygenases and cycloxygenases produces the group of eicosanoids molecules with many biological roles and activities in a variety of human diseases including cancer. In this review, we describe the biological activities of lipids with focus in eicosanoids and prostate cancer.

Keywords

Polyunsaturated fatty acids (PUFAs) Arachidonic acid Lipoxygenases Prostaglandins Hydroxyeicosatetraenoic acids (HETEs) 5-oxo-eicosatetraenoic acid (5-oxo-ETE) 

1 Introduction

Prostate cancer being the most common cancer and the first death cause in men has been extensively studied during the last decades, with great improvement in diagnosis and treatment approaches [35]. However, our knowledge on causative and progression factors is still rather limited. In fact, there is great need, to recognize factors that influence progression to a more aggressive/metastatic state, so that among men that are diagnosed at an early stage of the disease, populations at high risk could be identified and treated and/or advised appropriately. A large number of evidence from epidemiological as well as in vitro and in vivo studies have revealed an association of fatty acids and their metabolites with cancer incidence and mortality. In the present review, we will try to summarize the current knowledge on eicosanoids’ (metabolites of polyunsaturated fatty acids, PUFAs, such as arachidonic acid) influence on prostate cancer.

2 Eicosanoids

The term eicosanoids is used to describe a diverse group of PUFAs of 20 carbon units in length that includes arachidonic acid (an ω-6 fatty acid) and other similar PUFAs such as adrenic and dihomo-gamma-linolenic acid (ω-6 fatty acids), eicosapentaenoic (an ω-3 fatty acid) and mead acid (an ω-9 fatty acid), and their metabolites. The latter are important signaling molecules with an autocrine, paracrine, and endocrine action, involved in the function of different systems and organs such as immune, reproductive, gastrointestinal, and kidneys, regulating several physiological and pathological processes, such as cell growth, inflammation, allergy, pain perception, and blood pressure. The first step in arachidonic acid metabolism requires its release from cell membrane phospholipids, under the action of phospholipase A2 (PLA2), a process initiated by several stimuli like ischemia, mechanical trauma, hormones, growth factors, and cytokines. Subsequently, oxidation of arachidonic acid by different enzymes, such as cyclooxygenases (COXs), lipoxygenases (LOXs) cytochrome P450 epoxygenases (EPXs), or hydroxylases, leads to the production of the different eicosanoid molecules. Two major groups of eicosanoids have been described. The first one includes the so called classic eicosanoids like hydroxyeicosatetraenoic acids (HETEs), leukotrienes (LKs), eoxins (EXs), resolvins (RvEs), hydroxy-eicosapentaenoic acids (HEPEs) and prostanoids like prostaglandins (PGs), prostacyclins (PCs), and thromboxanes (TXs). The second one with the non-classic eicosanoids comprises of oxo-eicosanoids (oxo-ETEs), hepoxillins (Hxs), lipoxins (Lxs), epilipoxins (Epi-Lxs) epoxyeicosatrienoic acids (EETs), epoxyeicosatetranoic acids (EEQs), and isoprostanes (isoPs).

COXs are the enzymes responsible to produce prostaglandins, prostacyclins, and thromboxanes; LOXs for HETEs, lipoxins, hepoxilins, and leukotrienes; and P450-epoxygenases for EETs and HETEs (refer to Fig. 1 for the major eicosanoid molecules and the enzymes involved in their biosynthesis).
Fig. 1

Main eicosanoid biosynthesis pathways and the enzymes involved. HETE hydroxyeicosatetraenoic acid, HpETE hydroperoxyeicosatetraenoic acid, PG Prostaglandin, PC Prostacyclin, TX Thromboxane, 5-oxo-ETE 5-oxo-eicosatetraenoic acid, LT Leukotriene, LX Lipoxin, RvE Resolvin, CysLTs Cysteinyl Leukotrienes, PLA2 phospholipase A2 enzyme, LPAT lysophospholipid acyltransferase

3 Sources of fatty acids

3.1 Dietary

Arachidonic acid (AA, 20:4n-6) is the most abundant ω-6 fatty acid incorporated in cell membranes, along with the ω-3 series fatty acids such as eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). They are derivatives of linoleic acid (LA, 18:2n-6) and alpha-linolenic acid (α-LNA, 18:3n-3) respectively. They are essential fatty acids which they cannot be synthesized de novo and must be taken from the diet. Linoleic acid is abundant in vegetable oils while α-linolenic acid is found at moderate levels in most plants; its main source in the human diet is fish or fish oil. Therefore, their levels and subsequently the levels of their derivatives within the organism depend primarily on dietary intake and on the activity of the enzymes involved in their metabolism and biotransformation [13]. In fact, gene polymorphism of the various fatty acid metabolizing enzymes accounts for differences in fatty acid metabolism among individuals [53].

3.2 De novo

Cancer cells exhibit an altered metabolism, to cope with their increased proliferation rate. Alterations involve high glucose consumption for their energy needs and new molecules synthesis through their modified anabolic processes [18]. Indeed, there is a high demand for fatty acids, which apart from being building blocks in cell membranes can also be used to produce energy, modify proteins through lipoylation, and act as signaling molecules. Hence, under normal conditions, the production of fatty acids in cells other than adipose and lung tissue, brain, and liver, is relatively small, while in cancer, including prostate cancer, increased de novo production of fatty acids occurs along with a high dependence of cancer cells on exogenous fatty acid uptake and consumption, the latter through fatty acid β-oxidation (FAO) pathway [3].

Even though ω-3 and ω-6 series PUFAS cannot be synthesized de novo, there is an interconnection of de novo fatty acid synthesis with eicosanoids biosynthesis since malonyl-CoA that is produced by acetyl-CoA is also required for PUFA elongation to longer chain species. The key enzyme in de novo fatty acid synthesis is fatty acid synthase. Overexpression of the fatty acid synthase gene which is a common phenomenon in prostate tumors directly related to Akt/PKB activation, in combination with increased stabilization of fatty acid synthase by ubiquitin-specific protease-2a (USP2a) results in increased de novo fatty acid synthesis [56, 61]. Equally, overexpression of the sterol response element-binding protein-1c (SREBP-1c) that regulates the enzymes involved in this process leads to tumor growth in prostate and migration of cancer cells to distant organs [2, 17].

4 Role of fatty acid intake and metabolism in prostate cancer

4.1 Epidemiological evidence

First evidence for the existence of an association of lipid consumption and prostate cancer came from the observations that prostate cancer mortality rates are especially high in Northern Europe and America and much lower in Asian countries and that immigrates from Asia in America have an increased risk of developing prostate cancer. This suggests that dietary factors may account for this difference, since western diet, in contrast to eastern diet, contains higher levels of saturated fats [43]. However, epidemiological findings concerning the association of n-3 and n-6 PUFAS that are substrates for eicosanoid synthesis and prostate cancer risk are inconclusive. Several studies have reported that a high intake of PUFAS is either positively or weakly associated with prostate cancer along with a significant positive association between arachidonic acid and its metabolites in serum [47], while an inverse association was reported for n-3 PUFAS since their levels were found decreased in patients with benign prostatic hyperplasia and prostate cancer [66]. Indeed, a meta-analysis and an observational study, comparing high and low intake of alpha-linolenic acid found a small (significant) decrease in the risk for prostate cancer [10, 45]. This difference was explained by the fact that n-6 PUFAS are converted predominately into pro-inflammatory eicosanoids, while n-3 PUFAs are converted into anti-inflammatory or less pro-inflammatory eicosanoids [33]. Higher levels of n-6 and n-3 PUFAS (except EPA) in diet, as depicted in their higher distribution in red blood cells may be associated with higher-grade prostate cancer [67]. On the other hand, in several meta-analysis studies, no association for dietary intake was observed, but higher levels of alpha-linolenic acid in blood and adipose tissue were associated with increased risk of prostate cancer [7, 11, 52].

Inconclusive were also the findings from the alpha omega trial (a double-blind placebo-controlled trial of alpha-linolenic acid and the fish fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) on the recurrence of cardiovascular disease) in which PSA levels were measured initially and after consuming 2 g per day of alpha-linolenic acid for 40 months. A small but not significant increase in PSA was observed compared to the placebo group [8].

4.2 Changes in the biosynthesis of eicosanoids

As mentioned above, the first step for fatty acids metabolism is their release from phospholipids by the action of phospholipase A2 (PLA2) enzymes. Four major types of PLA2 enzymes (secretory sPLA2s; cytosolic cPLA2s and calcium-independent iPLA2s; acetyl hydrolase/oxidized lipid lipoprotein associated (Lp)PLA2s) have been identified with different selectivity for phospholipids with ω6 and ω3 PUFA [9]. Therefore, the release of fatty acids from phospholipids can be quite different between ω6 and ω3 PUFA, depending on the relative expression of the various phospholipases. Interestingly, in prostate cancer, it has been found that sPLA2 was upregulated, while inhibitors of cPLA2 were downregulated [19] indicating a possible increased release of ω6 PUFA, since ω3 PUFA (EPA or DHA) are poor substrates for cPLA2 [36, 46]. Additionally, the levels of sPLA2 were found to be increased in high Gleason grade prostate carcinomas and correlated with increased cell proliferation. Elevated activity of iPLA 2 has been also associated with malignant prostate tumor cells and prostate cancer cell growth [38].

After the release of fatty acids, COXs and LOXs are the main enzymes in the production of the different eicosanoids. They exist in different isoforms and their altered expression levels in cancer, including prostate cancer, have been extensively studied.

It has been found that COX-2 isoform is mainly expressed under the influence of certain stimuli, such as TNFα and that prostate cancer tumors express higher levels of COX-2 in relation to normal tissues and to the expression of COX-1. However, findings on COX-1 levels in prostate cancer cells compared to normal ones are rather contradictory. Uotila et al. showed that there was no difference in COX-1 expression between carcinoma and normal prostate samples [60], while Kirschenbaum et al. reported an upregulated expression of COX-1 in luminal epithelial prostate cancer cells [32]. Moreover, COX-2-enhanced expression by TNFα treatment was also found to be differentially distributed within normal (perinuclear) and prostate cancer cells (cytoplasmic) [54]. Increased COX-2 expression was also found after prostaglandin treatment of PC-3 and LNCaP cells for 4 days [59].

Similarly, differences in LOXs expression between cancerous and benign tumors or normal prostate tissue was investigated. Overexpression of 5-LOX in prostate cancer tissue specimens was first described by Gupta and his colleagues [27]. Overexpression of 5-LOX was further verified by findings of increased production of 5-HETE in malignant tumors. Similarly, 12-LOX was overexpressed in prostate cancer and was strongly associated with poor differentiation and invasiveness [22], since 12-LOX expression seems to stimulate angiogenesis [57]. Furthermore, it has been shown that leukotriene B4 (LTB4) levels were increased in prostate cancers [34]. On the other hand, a reduction on 15-Lox-2 and its product 15-HETE has been reported in prostate cancer compared to normal human prostate cells and suggested as a negative cell cycle regulator in normal human prostate epithelial cells [5, 51].

A rather interesting finding was that LOX products may exert a negative feedback on COX-1 gene expression in prostate cancer cells, as was revealed by cPLA(2) alpha inhibition that induced the expression of COX-1 and increased PGE2 levels and decreased most LOX products (HETEs), while replenishing 5- and 12-HETEs abolished this effect [41]. Moreover, prostate carcinomas have been also characterized by high thromboxane synthases levels compared to normal tissue and associated with advanced and high-grade disease [16, 64].

5 Eicosanoid effects on prostate cancer cells

Several experimental studies point out the significant action of eicosanoids on prostate cancer cells, affecting important cellular processes like cell proliferation, apoptosis, angiogenesis, and metastasis. However, their effects are rather heterogeneous. It has been found that, while n-3 PUFAS derived from alpha-linolenic acid such as EPA and DHA and their metabolites suppress prostate cancer cell growth, n-6 PUFAS such as arachidonic acid from linoleic acid promote prostate tumors. More specifically, linoleic acid and arachidonic acid have been shown to promote cell proliferation of prostate cancer cells both in vitro and in vivo [4, 12, 44, 48], while in tumor specimens from radical prostatectomy, arachidonic acid levels were low, due to increased metabolism, supported by increased amounts of PGE2 [12]. Indeed, PGE2 has been reported to promote carcinogenesis by modulating proliferation, apoptosis, migration and invasion, while inhibition of its production with cyclooxygenase inhibitors has the opposite effects [1, 12, 49]. The later led to an increased interest in utilizing such inhibitors/antagonists (old ones like NSAIDS or newly identified molecules) for therapeutic use [21, 49]. Indeed, an inhibitory effect on prostate cancer cell proliferation was observed by two COX-2 inhibitors, CAY10404 and celecoxib [6]. The latter was also tested in the multi-arm randomized controlled STAMPEDE trial, which failed to show a benefit in men with locally advanced or metastatic prostate cancer, under androgen deprivation therapy [14]. In a prostate-specific Pten knockout and omega-3 desaturase transgenic mouse model, COX-1, COX-2, and LOX-5 were further proved to promote tumor growth, while COX-1 was required for the protective effects of ω-3 PUFA, suggesting that ω-3 metabolites of COX-1 could suppress cancer growth [65]. Moreover, PGE2 has been reported to mediate the TGF-beta effects on prostate cancer cell migration and invasion in PC3 cells via activation of the PI3K/AKT/mTOR pathway [63].

Ghosh and his colleagues found a stimulatory effect of arachidonic acid on the proliferation of PC3 and LNCaP prostate cancer cells, an effect reverted by inhibitors of 5-LOX [23, 24], but not by COX inhibitors. This stimulatory effect was only mimicked by 5-oxo-ETE, while other 5-LOX metabolites such as leukotrienes were ineffective [24]. The effect of 5-oxo-ETE is mediated by OXER1 which has been identified in different cancers including prostate. Reduced expression of OXER1 was found to result in reduced cell viability of PC3 cells, pointing out the importance of this receptor and its endogenously produced ligand 5-oxo-ETE in the survival of prostate cancer cells [25, 42, 55]. This is quite important, since 5-oxo-ETE synthesis could be triggered by 5-HETE production by immune cells in the tumor microenvironment, such as neutrophils that exhibit high 5-LOX activity, as demonstrated by Grant and his colleagues [26]. Furthermore, we have recently shown that this receptor can act as a membrane-located receptor for androgens [29], having an antagonistic action, mediating testosterone’s previously described apoptotic, and antimigratory effects [15, 30, 31]. The precursor of 5-oxo-ETE, 5-HETE has also been suggested to promote survival of human prostate cancer cells [24]. Increased apoptosis of prostate cancer cells was also reported by Sarveswaran and his colleagues by MK591, a specific inhibitor of 5-LOX activity, that is, mediated via down-regulation of protein kinase C-epsilon [50]. 12(S) HETE, another arachidonic acid metabolite produced by LOX enzymes, has been reported to induce angiogenesis by stimulating VEGF expression in prostate cancer cells [37, 40].

As already mentioned, certain eicosanoid metabolites may function as tumor suppressors. This group includes EPA and DHA, derived from alpha-linolenic acid [20], which have been described to decrease the growth of LNCaP cells with a decreased expression of the androgen receptor and a suppressed Akt/mTOR signaling pathway [20]. EPA also inhibits voltage-gated sodium channels and invasiveness of PC3 prostate cancer cells [39]. Equally, the 15-LOX product, 15-HETE and 15-deoxy-Δ12,14-PGJ2, the metabolite of PGJ2, has been shown to suppress prostate cancer cell growth [58, 62] with the later acting as a potent AR inhibitor [28, 39].

6 Concluding remarks

All the above presented data provide a substantial amount of evidence that eicosanoids have a significant role in prostate cancer. Their levels in the blood and prostate tissue not only as a result of dietary intake and biotransformation but also due to their production by immune cells in the tumor microenvironment should be definitely taken into account and further explored. This will increase our knowledge on the mechanisms involved and will possibly provide new prevention and/or therapeutic strategies for prostate cancer.

References

  1. 1.
    Anderson, K. M., Wygodny, J. B., Ondrey, F., & Harris, J. (1988). Human PC-3 prostate cell line DNA synthesis is suppressed by eicosatetraynoic acid, an in vitro inhibitor of arachidonic acid metabolism. Prostate, 12(1), 3–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Beckers, A., Organe, S., Timmermans, L., Scheys, K., Peeters, A., Brusselmans, K., Verhoeven, G., & Swinnen, J. V. (2007). Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Research, 67(17), 8180–8187.  https://doi.org/10.1158/0008-5472.can-07-0389.CrossRefPubMedGoogle Scholar
  3. 3.
    Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016). Lipid metabolic reprogramming in cancer cells. Oncogenesis, 5, e189.  https://doi.org/10.1038/oncsis.2015.49.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Berquin, I. M., Min, Y., Wu, R., Wu, J., Perry, D., Cline, J. M., Thomas, M. J., Thornburg, T., Kulik, G., Smith, A., Edwards, I. J., D’Agostino Jr., R., Zhang, H., Wu, H., Kang, J. X., & Chen, Y. Q. (2007). Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. The Journal of Clinical Investigation, 117(7), 1866–1875.  https://doi.org/10.1172/JCI31494.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bhatia, B., Maldonado, C. J., Tang, S., Chandra, D., Klein, R. D., Chopra, D., Shappell, S. B., Yang, P., Newman, R. A., & Tang, D. G. (2003). Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. The Journal of Biological Chemistry, 278(27), 25091–25100.  https://doi.org/10.1074/jbc.M301920200.CrossRefPubMedGoogle Scholar
  6. 6.
    Bieniek, J., Childress, C., Swatski, M. D., & Yang, W. (2014). COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore/centromere proteins. Prostate, 74(10), 999–1011.  https://doi.org/10.1002/pros.22815.CrossRefPubMedGoogle Scholar
  7. 7.
    Brouwer, I. A., Katan, M. B., & Zock, P. L. (2004). Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis. The Journal of Nutrition, 134(4), 919–922.  https://doi.org/10.1093/jn/134.4.919.CrossRefPubMedGoogle Scholar
  8. 8.
    Brouwer, I. A., Geleijnse, J. M., Klaasen, V. M., Smit, L. A., Giltay, E. J., de Goede, J., Heijboer, A. C., Kromhout, D., & Katan, M. B. (2013). Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial. PLoS One, 8(12), e81519.  https://doi.org/10.1371/journal.pone.0081519.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Burke, J. E., & Dennis, E. A. (2009). Phospholipase A2 structure/function, mechanism, and signaling. Journal of Lipid Research, 50(Suppl), S237–S242.  https://doi.org/10.1194/jlr.R800033-JLR200.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Carayol, M., Grosclaude, P., & Delpierre, C. (2010). Prospective studies of dietary alpha-linolenic acid intake and prostate cancer risk: a meta-analysis. Cancer Causes & Control, 21(3), 347–355.  https://doi.org/10.1007/s10552-009-9465-1.CrossRefGoogle Scholar
  11. 11.
    Carleton, A. J., Sievenpiper, J. L., de Souza, R., McKeown-Eyssen, G., & Jenkins, D. J. (2013). Case-control and prospective studies of dietary alpha-linolenic acid intake and prostate cancer risk: a meta-analysis. BMJ Open, 3(5), e002280.  https://doi.org/10.1136/bmjopen-2012-002280.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chaudry, A. A., Wahle, K. W., McClinton, S., & Moffat, L. E. (1994). Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. International Journal of Cancer, 57(2), 176–180.CrossRefPubMedGoogle Scholar
  13. 13.
    Chen, Y. Q., Edwards, I. J., Kridel, S. J., Thornburg, T., & Berquin, I. M. (2007). Dietary fat-gene interactions in cancer. Cancer Metastasis Reviews, 26(3–4), 535–551.  https://doi.org/10.1007/s10555-007-9075-x.CrossRefPubMedGoogle Scholar
  14. 14.
    Cheung, A. S., & Grossmann, M. (2012). COX-2 inhibitors in prostate cancer treatment--hold your horses? Asian Journal of Andrology, 14(4), 518–519.  https://doi.org/10.1038/aja.2012.51.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dambaki, C., Kogia, C., Kampa, M., Darivianaki, K., Nomikos, M., Anezinis, P., Theodoropoulos, P. A., Castanas, E., & Stathopoulos, E. N. (2005). Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: study in paraffin tissue sections. BMC Cancer, 5, 148.  https://doi.org/10.1186/1471-2407-5-148.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Dassesse, T., de Leval, X., de Leval, L., Pirotte, B., Castronovo, V., & Waltregny, D. (2006). Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. European Urology, 50(5), 1021–1031; discussion 1031, doi: https://doi.org/10.1016/j.eururo.2006.01.036.
  17. 17.
    De Schrijver, E., Brusselmans, K., Heyns, W., Verhoeven, G., & Swinnen, J. V. (2003). RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Research, 63(13), 3799–3804.PubMedGoogle Scholar
  18. 18.
    DeBerardinis, R. J., & Chandel, N. S. (2016). Fundamentals of cancer metabolism. Science Advances, 2(5), e1600200.  https://doi.org/10.1126/sciadv.1600200.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Dong, Q., Patel, M., Scott, K. F., Graham, G. G., Russell, P. J., & Sved, P. (2006). Oncogenic action of phospholipase A2 in prostate cancer. Cancer Letters, 240(1), 9–16.  https://doi.org/10.1016/j.canlet.2005.08.012.CrossRefPubMedGoogle Scholar
  20. 20.
    Friedrichs, W., Ruparel, S. B., Marciniak, R. A., & deGraffenried, L. (2011). Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. Nutrition and Cancer, 63(5), 771–777.  https://doi.org/10.1080/01635581.2011.570892.CrossRefPubMedGoogle Scholar
  21. 21.
    Ganesh, T. (2015). Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2. Expert Opinion on Therapeutic Patents, 25(7), 837–844.  https://doi.org/10.1517/13543776.2015.1025752.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Gao, X., Grignon, D. J., Chbihi, T., Zacharek, A., Chen, Y. Q., Sakr, W., Porter, A. T., Crissman, J. D., Edson Pontes, J., Powell, I. J., & Honn, K. V. (1995). Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology, 46(2), 227–237.CrossRefPubMedGoogle Scholar
  23. 23.
    Ghosh, J., & Myers, C. E. (1997). Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochemical and Biophysical Research Communications, 235(2), 418–423.  https://doi.org/10.1006/bbrc.1997.6799.CrossRefPubMedGoogle Scholar
  24. 24.
    Ghosh, J., & Myers, C. E. (1998). Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 95(22), 13182–13187.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Grant, G. E., Rokach, J., & Powell, W. S. (2009). 5-Oxo-ETE and the OXE receptor. Prostaglandins & Other Lipid Mediators, 89(3–4), 98–104.  https://doi.org/10.1016/j.prostaglandins.2009.05.002.CrossRefGoogle Scholar
  26. 26.
    Grant, G. E., Rubino, S., Gravel, S., Wang, X., Patel, P., Rokach, J., & Powell, W. S. (2011). Enhanced formation of 5-oxo-6,8,11,14-eicosatetraenoic acid by cancer cells in response to oxidative stress, docosahexaenoic acid and neutrophil-derived 5-hydroxy-6,8,11,14-eicosatetraenoic acid. Carcinogenesis, 32(6), 822–828.  https://doi.org/10.1093/carcin/bgr044.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gupta, S., Srivastava, M., Ahmad, N., Sakamoto, K., Bostwick, D. G., & Mukhtar, H. (2001). Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer, 91(4), 737–743.CrossRefPubMedGoogle Scholar
  28. 28.
    Kaikkonen, S., Paakinaho, V., Sutinen, P., Levonen, A. L., & Palvimo, J. J. (2013). Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells. Molecular Endocrinology, 27(2), 212–223.  https://doi.org/10.1210/me.2012-1313.CrossRefPubMedGoogle Scholar
  29. 29.
    Kalyvianaki, K., Gebhart, V., Peroulis, N., Panagiotopoulou, C., Kiagiadaki, F., Pediaditakis, I., Aivaliotis, M., Moustou, E., Tzardi, M., Notas, G., Castanas, E., & Kampa, M. (2017). Antagonizing effects of membrane-acting androgens on the eicosanoid receptor OXER1 in prostate cancer. Scientific Reports, 7, 44418.  https://doi.org/10.1038/srep44418.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kampa, M., Papakonstanti, E. A., Hatzoglou, A., Stathopoulos, E. N., Stournaras, C., & Castanas, E. (2002). The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. The FASEB Journal, 16(11), 1429–1431.  https://doi.org/10.1096/fj.02-0131fje.CrossRefPubMedGoogle Scholar
  31. 31.
    Kampa, M., Theodoropoulou, K., Mavromati, F., Pelekanou, V., Notas, G., Lagoudaki, E. D., Nifli, A. P., Morel-Salmi, C., Stathopoulos, E. N., Vercauteren, J., & Castanas, E. (2011). Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer. The Journal of Pharmacology and Experimental Therapeutics, 337(1), 24–32.  https://doi.org/10.1124/jpet.110.177246.CrossRefPubMedGoogle Scholar
  32. 32.
    Kirschenbaum, A., Klausner, A. P., Lee, R., Unger, P., Yao, S., Liu, X. H., & Levine, A. C. (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56(4), 671–676.CrossRefPubMedGoogle Scholar
  33. 33.
    Kromhout, D., Giltay, E. J., Geleijnse, J. M., & Alpha Omega Trial, G. (2010). n-3 fatty acids and cardiovascular events after myocardial infarction. The New England Journal of Medicine, 363(21), 2015–2026.  https://doi.org/10.1056/NEJMoa1003603.CrossRefPubMedGoogle Scholar
  34. 34.
    Larre, S., Tran, N., Fan, C., Hamadeh, H., Champigneulles, J., Azzouzi, R., et al. (2008). PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins & Other Lipid Mediators, 87(1–4), 14–19.  https://doi.org/10.1016/j.prostaglandins.2008.05.001.CrossRefGoogle Scholar
  35. 35.
    Litwin, M. S., & Tan, H. J. (2017). The diagnosis and treatment of prostate cancer: a review. JAMA, 317(24), 2532–2542.  https://doi.org/10.1001/jama.2017.7248.CrossRefPubMedGoogle Scholar
  36. 36.
    Martin-Chouly, C. A., Menier, V., Hichami, A., Youmine, H., Noel, F., Pedrono, F., et al. (2000). Modulation of PAF production by incorporation of arachidonic acid and eicosapentaenoic acid in phospholipids of human leukemic monocyte-like cells THP-1. Prostaglandins & Other Lipid Mediators, 60(4–6), 127–135.CrossRefGoogle Scholar
  37. 37.
    McCabe, N. P., Selman, S. H., & Jankun, J. (2006). Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. Prostate, 66(7), 779–787.  https://doi.org/10.1002/pros.20360.CrossRefPubMedGoogle Scholar
  38. 38.
    Mirtti, T., Laine, V. J., Hiekkanen, H., Hurme, S., Rowe, O., Nevalainen, T. J., et al. (2009). Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. APMIS, 117(3), 151–161.  https://doi.org/10.1111/j.1600-0463.2008.00002.x.CrossRefPubMedGoogle Scholar
  39. 39.
    Nakajima, T., Kubota, N., Tsutsumi, T., Oguri, A., Imuta, H., Jo, T., Oonuma, H., Soma, M., Meguro, K., Takano, H., Nagase, T., & Nagata, T. (2009). Eicosapentaenoic acid inhibits voltage-gated sodium channels and invasiveness in prostate cancer cells. British Journal of Pharmacology, 156(3), 420–431.  https://doi.org/10.1111/j.1476-5381.2008.00059.x.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Nie, D., Krishnamoorthy, S., Jin, R., Tang, K., Chen, Y., Qiao, Y., Zacharek, A., Guo, Y., Milanini, J., Pages, G., & Honn, K. V. (2006). Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. The Journal of Biological Chemistry, 281(27), 18601–18609.  https://doi.org/10.1074/jbc.M601887200.CrossRefPubMedGoogle Scholar
  41. 41.
    Niknami, M., Vignarajan, S., Yao, M., Hua, S., Witting, P. K., Kita, Y., Shimizu, T., Sved, P., Patel, M. I., & Dong, Q. (2010). Decrease in expression or activity of cytosolic phospholipase A2alpha increases cyclooxygenase-1 action: a cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochimica et Biophysica Acta, 1801(7), 731–737.  https://doi.org/10.1016/j.bbalip.2010.03.003.CrossRefPubMedGoogle Scholar
  42. 42.
    O'Flaherty, J. T., Rogers, L. C., Paumi, C. M., Hantgan, R. R., Thomas, L. R., Clay, C. E., High, K., Chen, Y. Q., Willingham, M. C., Smitherman, P. K., Kute, T. E., Rao, A., Cramer, S. D., & Morrow, C. S. (2005). 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochimica et Biophysica Acta, 1736(3), 228–236.  https://doi.org/10.1016/j.bbalip.2005.08.009.CrossRefPubMedGoogle Scholar
  43. 43.
    Ogce, F., Ceber, E., Ekti, R., & Oran, N. T. (2008). Comparison of mediterranean, Western and Japanese diets and some recommendations. Asian Pacific Journal of Cancer Prevention, 9(2), 351–356.PubMedGoogle Scholar
  44. 44.
    Pandalai, P. K., Pilat, M. J., Yamazaki, K., Naik, H., & Pienta, K. J. (1996). The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Research, 16(2), 815–820.PubMedGoogle Scholar
  45. 45.
    Pelser, C., Mondul, A. M., Hollenbeck, A. R., & Park, Y. (2013). Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiology, Biomarkers & Prevention, 22(4), 697–707.  https://doi.org/10.1158/1055-9965.EPI-12-1196-T.CrossRefGoogle Scholar
  46. 46.
    Pickett, W. C., & Ramesha, C. S. (1987). Ether phospholipids in control and 20:4-depleted rat PMN: additional evidence for a 1-O-alkyl-2-20:4-sn-glycerol-3-phosphocholine specific phospholipase A2. Agents and Actions, 21(3–4), 390–392.CrossRefPubMedGoogle Scholar
  47. 47.
    Rodriguez-Blanco, G., Burgers, P. C., Dekker, L. J., Ijzermans, J. J., Wildhagen, M. F., Schenk-Braat, E. A., et al. (2014). Serum levels of arachidonic acid metabolites change during prostate cancer progression. Prostate, 74(6), 618–627.  https://doi.org/10.1002/pros.22779.CrossRefPubMedGoogle Scholar
  48. 48.
    Rose, D. P., & Connolly, J. M. (1991). Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate, 18(3), 243–254.CrossRefPubMedGoogle Scholar
  49. 49.
    Ruan, D., & So, S. P. (2014). Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo. Life Sciences, 116(1), 43–50.  https://doi.org/10.1016/j.lfs.2014.07.042.CrossRefPubMedGoogle Scholar
  50. 50.
    Sarveswaran, S., Thamilselvan, V., Brodie, C., & Ghosh, J. (2011). Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochimica et Biophysica Acta, 1813(12), 2108–2117.  https://doi.org/10.1016/j.bbamcr.2011.07.015.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Shappell, S. B., Manning, S., Boeglin, W. E., Guan, Y. F., Roberts, R. L., Davis, L., Olson, S. J., Jack, G. S., Coffey, C. S., Wheeler, T. M., Breyer, M. D., & Brash, A. R. (2001). Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia, 3(4), 287–303.  https://doi.org/10.1038/sj/neo/7900166.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Simon, J. A., Chen, Y. H., & Bent, S. (2009). The relation of alpha-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis. The American Journal of Clinical Nutrition, 89(5), 1558S–1564S.  https://doi.org/10.3945/ajcn.2009.26736E.CrossRefPubMedGoogle Scholar
  53. 53.
    Simopoulos, A. P. (2010). Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Experimental Biology and Medicine (Maywood, N.J.), 235(7), 785–795.  https://doi.org/10.1258/ebm.2010.009298.CrossRefGoogle Scholar
  54. 54.
    Subbarayan, V., Sabichi, A. L., Llansa, N., Lippman, S. M., & Menter, D. G. (2001). Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Research, 61(6), 2720–2726.PubMedGoogle Scholar
  55. 55.
    Sundaram, S., & Ghosh, J. (2006). Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochemical and Biophysical Research Communications, 339(1), 93–98.  https://doi.org/10.1016/j.bbrc.2005.10.189.CrossRefPubMedGoogle Scholar
  56. 56.
    Swinnen, J. V., Roskams, T., Joniau, S., Van Poppel, H., Oyen, R., Baert, L., et al. (2002). Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. International Journal of Cancer, 98(1), 19–22.CrossRefPubMedGoogle Scholar
  57. 57.
    Tang, K., & Honn, K. V. (1999). 12(S)-HETE in cancer metastasis. Advances in Experimental Medicine and Biology, 447, 181–191.CrossRefPubMedGoogle Scholar
  58. 58.
    Tang, S., Bhatia, B., Maldonado, C. J., Yang, P., Newman, R. A., Liu, J., Chandra, D., Traag, J., Klein, R. D., Fischer, S. M., Chopra, D., Shen, J., Zhau, H. E., Chung, L. W. K., & Tang, D. G. (2002). Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. The Journal of Biological Chemistry, 277(18), 16189–16201.  https://doi.org/10.1074/jbc.M111936200.CrossRefPubMedGoogle Scholar
  59. 59.
    Tjandrawinata, R. R., Dahiya, R., & Hughes-Fulford, M. (1997). Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. British Journal of Cancer, 75(8), 1111–1118.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Uotila, P., Valve, E., Martikainen, P., Nevalainen, M., Nurmi, M., & Harkonen, P. (2001). Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urological Research, 29(1), 23–28.CrossRefPubMedGoogle Scholar
  61. 61.
    Van de Sande, T., Roskams, T., Lerut, E., Joniau, S., Van Poppel, H., Verhoeven, G., et al. (2005). High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. The Journal of Pathology, 206(2), 214–219.  https://doi.org/10.1002/path.1760.CrossRefPubMedGoogle Scholar
  62. 62.
    Vanaja, D. K., Grossmann, M. E., Celis, E., & Young, C. Y. (2000). Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Research, 60(17), 4714–4718.PubMedGoogle Scholar
  63. 63.
    Vo, B. T., Morton Jr., D., Komaragiri, S., Millena, A. C., Leath, C., & Khan, S. A. (2013). TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology, 154(5), 1768–1779.  https://doi.org/10.1210/en.2012-2074.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Wang, M. T., Honn, K. V., & Nie, D. (2007). Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Reviews, 26(3–4), 525–534.  https://doi.org/10.1007/s10555-007-9096-5.CrossRefPubMedGoogle Scholar
  65. 65.
    Wang, S., Wu, J., Suburu, J., Gu, Z., Cai, J., Axanova, L. S., Cramer, S. D., Thomas, M. J., Perry, D. L., Edwards, I. J., Mucci, L. A., Sinnott, J. A., Loda, M. F., Sui, G., Berquin, I. M., & Chen, Y. Q. (2012). Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis, 33(2), 404–412.  https://doi.org/10.1093/carcin/bgr290.CrossRefPubMedGoogle Scholar
  66. 66.
    Yang, Y. J., Lee, S. H., Hong, S. J., & Chung, B. C. (1999). Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry, 32(6), 405–409.CrossRefPubMedGoogle Scholar
  67. 67.
    Zhao, Z., Reinstatler, L., Klaassen, Z., Xu, Y., Yang, X., Madi, R., Terris, M. K., Qian, S. Y., Kelavkar, U., & Moses, K. A. (2016). The association of fatty acid levels and Gleason grade among men undergoing radical prostatectomy. PLoS One, 11(11), e0166594.  https://doi.org/10.1371/journal.pone.0166594.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Athanassios A. Panagiotopoulos
    • 1
  • Konstantina Kalyvianaki
    • 1
  • Elias Castanas
    • 1
  • Marilena Kampa
    • 1
    Email author
  1. 1.Laboratory of Experimental Endocrinology, School of MedicineUniversity of CreteHeraklionGreece

Personalised recommendations